What is Aurealis Pharma?
Aurealis Pharma specializes in the development of innovative multi-target cell and gene therapies designed to address critical unmet medical needs. Their therapeutic focus spans chronic wounds, cancer, and inflammatory diseases, with a particular emphasis on complex, multi-factorial conditions such as diabetic foot ulcers and various oncological indications. The company's scientific platform is geared towards advancing evidence-based treatments to improve patient outcomes, aiming for scalable and cost-effective solutions in regenerative medicine and oncology.
How much funding has Aurealis Pharma raised?
Aurealis Pharma has raised a total of $10.8M across 3 funding rounds:
Angel/Seed
$1.8M
Angel/Seed
$3.3M
Series A
$5.8M
Angel/Seed (2014): $1.8M with participation from Tekes
Angel/Seed (2016): $3.3M led by Finnvera plc
Series A (2017): $5.8M supported by Finnvera plc and Tekes
Key Investors in Aurealis Pharma
Finnvera plc
Finnvera plc is a specialized financing company owned by the State of Finland, acting as the official Export Credit Agency. They provide financing and guarantees to support the growth and internationalization of Finnish enterprises, sharing risks with other financial institutions.
Tekes
Tekes, now Business Finland, offers funding for researchers to commercialize their ideas, focusing on identifying market opportunities and developing strategies for commercial success.
Tekes
Tekes, now Business Finland, offers funding for researchers to commercialize their ideas, focusing on identifying market opportunities and developing strategies for commercial success.
What's next for Aurealis Pharma?
The recent major strategic investment positions Aurealis Pharma for accelerated development and market penetration. With a foundation built on robust scientific research and a clear focus on complex diseases, the company is poised to further its pipeline of cell and gene therapies. Future endeavors will likely involve advancing clinical trials, expanding manufacturing capabilities, and forging strategic partnerships to bring their innovative treatments to patients globally. The sustained backing from key financial entities suggests confidence in Aurealis Pharma's long-term vision and therapeutic potential.
See full Aurealis Pharma company page
